In a patient with prostate adenocarcinoma grade group 2 (Gleason score 3 + 4 = 7) and a PSA of 37 ng/mL, what is the recommended treatment?

Treatment Recommendation for Grade Group 2 Prostate Cancer with PSA 37 ng/mL

This patient requires immediate active treatment with radical prostatectomy or radiotherapy plus androgen deprivation therapy (ADT), NOT active surveillance, due to the markedly elevated PSA of 37 ng/mL which places him at very high risk for disease progression and metastasis.

Staging Assessment

Before finalizing treatment, complete staging workup is essential:

• Multiparametric MRI of the pelvis to assess extraprostatic extension and lymph node involvement
• Bone scan or PSMA PET/CT to rule out metastatic disease (PSA >20 ng/mL carries high risk of occult metastases)
• CT abdomen/pelvis for nodal staging

The PSA of 37 ng/mL automatically classifies this as high-risk or very high-risk localized disease (or potentially locally advanced/metastatic), regardless of the Grade Group 2 histology 1.

Why Active Surveillance is NOT Appropriate

While Grade Group 2 (Gleason 3+4=7) can be managed with active surveillance in highly selected cases, this patient is definitively excluded from surveillance protocols due to:

1. PSA >20 ng/mL: Research demonstrates that PSA ≥20 ng/mL predicts very poor biochemical control in Gleason 7 patients treated with radiation alone, with 5-year biochemical disease-free rates of only 21% 2. This threshold far exceeds any guideline criteria for surveillance.

2. Guideline criteria violation: The EAU guidelines specify that AS for Grade Group 2 requires PSA <10 ng/mL, among other favorable features 1. This patient's PSA of 37 ng/mL is nearly 4-fold higher than the maximum acceptable threshold.

3. High metastatic risk: The combination of Grade Group 2 with PSA >20 ng/mL suggests aggressive biology requiring multimodal therapy 2.

Treatment Algorithm Based on Staging Results

If M0 Disease (No Metastases):

Option 1: Radical Prostatectomy

• Indicated if life expectancy >10 years and no significant comorbidities
• Extended pelvic lymph node dissection is mandatory given high-risk features
• Consider nerve-sparing only if imaging shows no extracapsatic extension on that side 1

Option 2: Radiotherapy + Long-term ADT (Preferred for high-risk)

• IMRT/VMAT with IGRT: 76-78 Gy conventional fractionation OR moderate hypofractionation (60 Gy/20 fractions or 70 Gy/28 fractions)
• Combined with ADT for 18-36 months (long-term, not the 4-6 months used for intermediate-risk) 1
• Doses ≥76 Gy are critical for Gleason 7 tumors; lower doses result in only 54% 5-year biochemical control versus 76% with adequate dosing 2
• Consider brachytherapy boost (LDR or HDR) combined with external beam if urinary function is good 1

Option 3: Consider Intensification with Abiraterone

• For very high-risk M0 disease, adding abiraterone acetate to ADT + radiotherapy has shown benefit in the STAMPEDE trial 1
• This applies particularly if imaging reveals N1 disease or other very high-risk features

If M1 Disease (Metastases Present):

Systemic therapy becomes primary:

• ADT + novel androgen receptor pathway inhibitor (abiraterone or enzalutamide) + docetaxel (triplet therapy)
• This represents standard of care for metastatic hormone-sensitive prostate cancer
• Radiotherapy to prostate may still be considered for local control/palliation

Critical Pitfalls to Avoid

1. Do not delay staging: With PSA 37 ng/mL, there is substantial risk of metastatic disease that would completely change management
2. Do not use intermediate-risk protocols: The short-term ADT (4-6 months) recommended for intermediate-risk disease 1 is inadequate here; this patient needs 18-36 months minimum
3. Do not undertreated with radiation dose: Historical data shows Gleason 7 patients with PSA >10 ng/mL need ≥76 Gy; lower doses result in poor outcomes 2, 3
4. Do not consider active surveillance: Despite Grade Group 2 histology, the PSA level absolutely contraindicates surveillance 1, 4

Percentage of Gleason Pattern 4 Matters

If pathology review reveals:

• <10% pattern 4: Still not eligible for AS due to PSA, but may have slightly better prognosis
• >25% pattern 4 or cribriform/intraductal histology: Confirms need for aggressive treatment and excludes any consideration of surveillance 1, 5

The definitive treatment choice between surgery and radiation depends on patient age, comorbidities, baseline urinary/sexual function, and final staging, but both require aggressive multimodal approaches given the high-risk presentation.